Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for XIST returned no results
Showing 76 to 90 of 1556 results for list

  1. Gallstone disease: diagnosis and management (CG188)

    This guideline covers diagnosing and managing gallstone disease in adults. It aims to reduce variation in care by promoting the most effective treatments, and to improve the advice given to people with gallstone disease before and after treatment.

  2. Head injury (QS74) update

    In development Reference number: GID-QS10189 Expected publication date:  07 January 2027

  3. Ex-situ machine perfusion devices for deceased donor liver transplants

    In development Reference number: GID-HTE10066 Expected publication date:  20 August 2026

  4. About indicators

    Our indicators measure outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.

  5. Suspected sepsis: recognition, diagnosis and early management - procalcitonin testing

    In development Reference number: GID-NG10467 Expected publication date:  15 July 2026

  6. Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304)

    Evidence-based recommendations on artificial hips and hip resurfacing for treating end-stage arthritis of the hip in adults.

  7. Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)

    This interim process statement sets out to guide the development of 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs). It provides an overview of the key process principles and describes all stages of development for ESUOMs

  8. Patient group directions (MPG2)

    This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.

  9. Managing common infections - antimicrobial prescribing guidelines

    In development Reference number: GID-NG10050 Expected publication date: TBC

  10. Aggressive behaviour in people receiving NHS or social care

    In development Reference number: GID-QS10196 Expected publication date:  28 January 2027

  11. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317

    In development Reference number: GID-TA11340 Expected publication date: TBC

  12. Remdesivir for treating COVID-19 [ID3808]

    Awaiting development Reference number: GID-TA10721 Expected publication date: TBC

  13. Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

    Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.

  14. Tofacitinib for treating juvenile idiopathic arthritis (TA735)

    Evidence-based recommendations on tofacitinib for treating juvenile idiopathic arthritis.

  15. Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]

    In development Reference number: GID-TA10832 Expected publication date: TBC